JP5563466B2 - 新規ピペラジノ−ジヒドロチエノピリミジン誘導体 - Google Patents

新規ピペラジノ−ジヒドロチエノピリミジン誘導体 Download PDF

Info

Publication number
JP5563466B2
JP5563466B2 JP2010529385A JP2010529385A JP5563466B2 JP 5563466 B2 JP5563466 B2 JP 5563466B2 JP 2010529385 A JP2010529385 A JP 2010529385A JP 2010529385 A JP2010529385 A JP 2010529385A JP 5563466 B2 JP5563466 B2 JP 5563466B2
Authority
JP
Japan
Prior art keywords
het
alkyl
alkylene
aryl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010529385A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011500638A (ja
JP2011500638A5 (https=
Inventor
パスカル プーゼ
クリシュトフ ヘンケ
ペーター ニコラウス
ロルフ ゲーゲル
トーマス フォックス
デニス フィーゲン
クラウス クリンダー
Original Assignee
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング filed Critical ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2011500638A publication Critical patent/JP2011500638A/ja
Publication of JP2011500638A5 publication Critical patent/JP2011500638A5/ja
Application granted granted Critical
Publication of JP5563466B2 publication Critical patent/JP5563466B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epidemiology (AREA)
JP2010529385A 2007-10-19 2008-10-16 新規ピペラジノ−ジヒドロチエノピリミジン誘導体 Active JP5563466B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07118906 2007-10-19
EP07118906.2 2007-10-19
PCT/EP2008/063970 WO2009050236A1 (de) 2007-10-19 2008-10-16 Neue piperazino-dihydrothienopyrimidin-derivate

Publications (3)

Publication Number Publication Date
JP2011500638A JP2011500638A (ja) 2011-01-06
JP2011500638A5 JP2011500638A5 (https=) 2011-12-01
JP5563466B2 true JP5563466B2 (ja) 2014-07-30

Family

ID=39154598

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010529385A Active JP5563466B2 (ja) 2007-10-19 2008-10-16 新規ピペラジノ−ジヒドロチエノピリミジン誘導体

Country Status (6)

Country Link
US (2) US8486948B2 (https=)
EP (1) EP2215093B1 (https=)
JP (1) JP5563466B2 (https=)
AT (1) ATE537175T1 (https=)
CA (1) CA2702518A1 (https=)
WO (1) WO2009050236A1 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1847543A1 (de) 2006-04-19 2007-10-24 Boehringer Ingelheim Pharma GmbH & Co. KG Dihydrothienopyrimidine zur Behandlung von entzündlichen Erkrankungen
WO2009050236A1 (de) 2007-10-19 2009-04-23 Boehringer Ingelheim International Gmbh Neue piperazino-dihydrothienopyrimidin-derivate
AU2008313660B2 (en) 2007-10-19 2013-11-07 Boehringer Ingelheim International Gmbh Substituted piperidino-dihydrothienopyrimidines
EP2205609B1 (de) 2007-10-19 2017-03-29 Boehringer Ingelheim International GmbH Heterocyclus-substituierte piperazino-dihydrothienopyrimidine
US10065960B2 (en) 2010-04-02 2018-09-04 Ogeda Sa NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders
EP2552920B1 (en) 2010-04-02 2017-03-15 Ogeda Sa Novel nk-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in nk-3 receptors mediated disorders
US9802954B2 (en) 2011-08-24 2017-10-31 Boehringer Ingelheim International Gmbh Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma
US20130059866A1 (en) 2011-08-24 2013-03-07 Boehringer Ingelheim International Gmbh Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma
WO2013050424A1 (en) 2011-10-03 2013-04-11 Euroscreen S.A. NOVEL CHIRAL N-ACYL-5,6,7,(8-SUBSTITUTED)-TETRAHYDRO-[1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR MEDIATED DISORDERS AND CHIRAL SYNTHESIS THEREOF
RU2637925C2 (ru) * 2012-01-10 2017-12-08 Ф. Хоффманн-Ля Рош Аг Соединения тиенопиримидина
US9422267B2 (en) 2012-12-26 2016-08-23 Medivation Technologies, Inc. Fused pyrimidine compounds and use thereof
KR102151292B1 (ko) 2013-01-31 2020-09-02 가부시키가이샤 무라타 세이사쿠쇼 압전 진동체
TW201512189A (zh) 2013-04-16 2015-04-01 Gruenenthal Chemie 新型被取代之嘧啶縮合化合物
MX389276B (es) * 2016-12-26 2025-03-20 Meiji Seika Pharma Co Ltd Compuesto novedoso y sal de este aceptable desde el punto de vista farmacologico.
WO2019057806A1 (en) 2017-09-20 2019-03-28 Leo Pharma A/S SUBSTITUTED DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS
ES2968822T3 (es) 2017-12-15 2024-05-14 Union Therapeutics As Azetidina dihidrotienopirimidinas sustituidas y su uso como inhibidores de la fosfodiesterasa
PT3724196T (pt) 2017-12-15 2023-01-13 Union Therapeutics As Azetidina di-hidrotienopiridinas substituídas e a sua utilização como inibidores de fosfodiesterase
EP3724195B1 (en) 2017-12-15 2023-12-27 UNION therapeutics A/S Substituted tetrahydropyran dihydrothienopyrimidines and their use as phosphodiesterase inhibitors
CN111961034A (zh) * 2019-05-20 2020-11-20 浙江同源康医药股份有限公司 用作ret激酶抑制剂的化合物及其应用
EP4155308A4 (en) * 2020-07-14 2024-04-17 Wuhan LL Science and Technology Development Co., Ltd. ROCK INHIBITOR, METHOD FOR PREPARING IT AND ITS USE
TW202402289A (zh) * 2022-06-02 2024-01-16 大陸商西藏海思科製藥有限公司 Pde4b抑制劑及其用途
EP4570804A1 (en) * 2022-08-09 2025-06-18 Xizang Haisco Pharmaceutical Co., Ltd. Pde4b inhibitor and use thereof
US20260008788A1 (en) * 2022-09-29 2026-01-08 Suzhou Ark Biopharmaceutical Co., Ltd. Aza-fused ring compound, preparation method therefor, and use thereof in medicine
CN120752243A (zh) * 2023-04-13 2025-10-03 上海壹迪生物技术有限公司 取代的二氢噻吩并嘧啶类化合物、其制备方法和应用
WO2025038987A2 (en) * 2023-08-17 2025-02-20 Katalytic Therapeutics, Inc. Pde4 protein degraders, pharmaceutical compositions, and therapeutic applications
CN121889398A (zh) * 2023-09-25 2026-04-17 苏州爱科百发生物医药技术有限公司 氮杂稠环类化合物及其制备方法和用途
WO2025162289A2 (zh) * 2024-02-04 2025-08-07 西藏海思科制药有限公司 一种pde4b抑制剂的晶型及其在医药上的用途
WO2025162431A1 (zh) * 2024-02-04 2025-08-07 西藏海思科制药有限公司 一种pde4b抑制剂化合物的口服药物组合物及其制备方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1470336A1 (de) 1962-07-04 1969-03-20 Thomae Gmbh Dr K Neue Dihydrothieno-[3,4-d]-pyrimidine und Verfahren zu ihrer Herstellung
NL122810C (https=) 1963-06-17
DE1470356A1 (de) 1964-01-15 1970-04-30 Thomae Gmbh Dr K Neue Thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung
DE2032687A1 (en) 1970-07-02 1972-01-05 Dr. Karl Thomae Gmbh, 7950 Biberach Cardiovascular 2-aminoalkylamino-thienopyrimidines - and 4-morpholino derivatives from 4-diethanolamino-compounds by intramolecular cyclisa
DE1940572A1 (de) 1969-08-08 1971-02-11 Thomae Gmbh Dr K Neue 2-Aminoalkylamino-thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung
BE754606A (fr) 1969-08-08 1971-02-08 Thomae Gmbh Dr K Nouvelles 2-aminoalcoylamino-thieno(3,2-d)pyrimidines et leurs procedesde fabrication
US3763156A (en) 1970-01-28 1973-10-02 Boehringer Sohn Ingelheim 2-heterocyclic amino-4-morpholinothieno(3,2-d)pyrimidines
FR2082496A5 (https=) 1970-03-18 1971-12-10 Westinghouse Freins & Signaux
DE2121950A1 (en) 1971-05-04 1972-11-23 Dr. Karl Thomae Gmbh, 7950 Biberach Thieno(3,2-d)pyrimidine derivs - with thrombocyte aggregation inhibiting activity
DE2750288A1 (de) 1977-11-10 1979-05-17 Thomae Gmbh Dr K Neue 9-(omega-heteroarylamino- alkylamino)-erythromycine, ihre salze, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
US4256737A (en) 1979-06-11 1981-03-17 Syntex (U.S.A.) Inc. Long acting depot injectable formulations for LH-RH analogues
US5187168A (en) 1991-10-24 1993-02-16 American Home Products Corporation Substituted quinazolines as angiotensin II antagonists
JPH07330777A (ja) 1994-06-08 1995-12-19 Taisho Pharmaceut Co Ltd チエノ［３，２−ｄ］ピリミジン−４−オン誘導体
JPH09301958A (ja) 1996-05-09 1997-11-25 Nippon Shoji Kk 新規ピリミジン化合物及び抗ロタウイルス剤
US6339089B2 (en) 1997-08-13 2002-01-15 Fujirebio Inc. Pyrimidine nucleus-containing compound and a medicament containing the same for a blood oxygen partial pressure amelioration, and a method for preparing the same
DE10064994A1 (de) 2000-12-23 2002-07-04 Merck Patent Gmbh Sulfamidothienopyrimidine
US6849638B2 (en) * 2001-04-30 2005-02-01 Bayer Pharmaceuticals Corporation 4-amino-5,6-substituted thiopheno [2,3-d] pyrimidines, pharmaceutical compositions containing the same, and their use in the treatment or prevention of pde7b-mediated diseases and conditions
US6587548B2 (en) 2001-07-17 2003-07-01 Hewlett-Packard Development Co., L.P. Method and system of using a single telephone number for multiple services
WO2003055890A1 (en) 2001-12-21 2003-07-10 Bayer Pharmaceuticals Corporation Thienopyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
DE60320933D1 (de) 2002-01-10 2008-06-26 Bayer Healthcare Ag Rho-kinase inhibitoren
EA008596B1 (ru) 2003-04-29 2007-06-29 Пфайзер Инк. 5,7-ДИАМИНОПИРАЗОЛО[4,3-d]ПИРИМИДИНЫ, ПОЛЕЗНЫЕ ПРИ ЛЕЧЕНИИ ГИПЕРТЕНЗИИ
JP2005003345A (ja) 2003-05-21 2005-01-06 Showa Denko Kk 換気兼熱交換装置および空調システム
KR20140119198A (ko) 2003-10-02 2014-10-08 디에스엠 아이피 어셋츠 비.브이. 변형량의 염소 및 칼륨을 사용하는 미세조류 중에 고농도 디에치에이의 생산
MY141220A (en) 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
WO2005082865A1 (ja) 2004-02-27 2005-09-09 Astellas Pharma Inc. 縮合二環性ピリミジン誘導体
EP1847543A1 (de) 2006-04-19 2007-10-24 Boehringer Ingelheim Pharma GmbH & Co. KG Dihydrothienopyrimidine zur Behandlung von entzündlichen Erkrankungen
MX2007012313A (es) 2006-04-19 2007-11-21 Boehringer Ingelheim Int Dihidrotienopirimidinas para el tratamiento de enfermedades inflamatorias.
EA015821B1 (ru) 2007-04-20 2011-12-30 Глэксо Груп Лимитед Трициклические азотсодержащие соединения в качестве антибактериальных агентов
US8653282B2 (en) 2007-10-18 2014-02-18 Boehringer Ingelheim International Gmbh Preparation of dihydrothieno [3,2-D] pyrimidines and intermediates used therein
FR2922550B1 (fr) 2007-10-19 2009-11-27 Sanofi Aventis Nouveaux derives de 6-aryl/heteroalkyloxy benzothiazole et benzimidazole, application comme medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de cmet
US20110028441A1 (en) 2007-10-19 2011-02-03 Boehringer Ingelheim International Gmbh Novel phenyl-substituted piperazino-dihydrothienopyrimidines
AR068888A1 (es) 2007-10-19 2009-12-16 Schering Corp Derivados de 1, 3, 4 - tiadiazol, una composicion farmaceutica que los comprende y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de la quinesina ksp.
WO2009050236A1 (de) 2007-10-19 2009-04-23 Boehringer Ingelheim International Gmbh Neue piperazino-dihydrothienopyrimidin-derivate
EP2205609B1 (de) 2007-10-19 2017-03-29 Boehringer Ingelheim International GmbH Heterocyclus-substituierte piperazino-dihydrothienopyrimidine
PE20090875A1 (es) 2007-10-19 2009-08-08 Astrazeneca Ab Derivados de tetrazol como moduladores de los receptores de glutamato metabotropicos
AU2008313660B2 (en) 2007-10-19 2013-11-07 Boehringer Ingelheim International Gmbh Substituted piperidino-dihydrothienopyrimidines
US9161927B2 (en) 2009-02-27 2015-10-20 Boehringer Ingelheim International Gmbh Drug combinations containing PDE4 inhibitors and NSAIDs
CA2753597A1 (en) 2009-02-27 2010-09-02 Boehringer Ingelheim International Gmbh Drug combinations containing pde4-inhibitors and nsaids
US20130059866A1 (en) 2011-08-24 2013-03-07 Boehringer Ingelheim International Gmbh Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma

Also Published As

Publication number Publication date
CA2702518A1 (en) 2009-04-23
JP2011500638A (ja) 2011-01-06
US8486948B2 (en) 2013-07-16
US9090626B2 (en) 2015-07-28
ATE537175T1 (de) 2011-12-15
US20110046096A1 (en) 2011-02-24
US20130274264A1 (en) 2013-10-17
EP2215093A1 (de) 2010-08-11
WO2009050236A1 (de) 2009-04-23
EP2215093B1 (de) 2011-12-14

Similar Documents

Publication Publication Date Title
JP5563466B2 (ja) 新規ピペラジノ−ジヒドロチエノピリミジン誘導体
JP5341899B2 (ja) ヘテロ環置換ピペラジノ−ジヒドロチエノピリミジン
CN101827852B (zh) 取代的哌啶子基-二氢噻吩并嘧啶
JP5214588B2 (ja) 炎症性疾患の治療のためのジヒドロチエノピリミジン
JP2011500621A (ja) 新規フェニル置換ピペラジノ−ジヒドロチエノピリミジン
HK1128636A (en) Dihydrothienopyrimidine for treating inflammatory disorders
HK1145677B (en) Substituted piperidino-dihydrothienopyrimidines

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111014

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111014

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130814

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20130815

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131113

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131213

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140602

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140612

R150 Certificate of patent or registration of utility model

Ref document number: 5563466

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250